US20030129259A1 - Topical lightening compostitions and methods of use - Google Patents

Topical lightening compostitions and methods of use Download PDF

Info

Publication number
US20030129259A1
US20030129259A1 US10/034,186 US3418601A US2003129259A1 US 20030129259 A1 US20030129259 A1 US 20030129259A1 US 3418601 A US3418601 A US 3418601A US 2003129259 A1 US2003129259 A1 US 2003129259A1
Authority
US
United States
Prior art keywords
composition
agent
melanin
topical
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/034,186
Inventor
Harish Mahalingam
Brian Jones
Gopinathan Menon
Christos Kyrou
Michael Traudt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avon Products Inc
Original Assignee
Avon Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Products Inc filed Critical Avon Products Inc
Priority to US10/034,186 priority Critical patent/US20030129259A1/en
Assigned to AVON PRODUCTS, INC. reassignment AVON PRODUCTS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JONES, BRIAN, KYROU, CHRISTOS D., MAHALINGAM, HARISH, MENON, GOPINATHAN K., TRAUDT, MICHAEL
Assigned to AVON PRODUCTS, INC. reassignment AVON PRODUCTS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JONES, BRIAN, TRAUDT, MICHAEL, MAHALINGAM, HARISH, KYROU, CHRISTOS D., MENON, GOPINATHAN K.
Publication of US20030129259A1 publication Critical patent/US20030129259A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/08Preparations for bleaching the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/96Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70Biological properties of the composition as a whole

Abstract

There is provided a topical lightening composition having a melanin synthesis-regulating agent and a vehicle. There is also provided a topical lightening composition having an extract of perilla leaf and a vehicle. There is also provided a topical lightening composition having a lightening agent selected from the group consisting of coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and any combinations thereof, along with a vehicle. The compositions and methods of the invention are effective to lighten skin, hair, lips, and/or nails.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0001]
  • The present invention relates to the lightening of the skin, hair, nails and/or lips. The present invention further relates to compositions and methods for lightening the skin, hair, nails and/or lips. [0002]
  • 2. Description of the Prior Art [0003]
  • Consumers, particularly those in Asia, have sought to lighten and reduce uneven pigmentation in the skin. Common skin conditions treated include freckles, age spots, dark spots, hyperpigmentation, discoloration, melasma, yellowing, and dark circles under the eyes. [0004]
  • Numerous substances have been applied to the skin to lighten the skin. Such substances include hydroquinone, kojic acid, licorice and/or its derivatives, ascorbic acid/ascorbic acid derivatives, arbutin, bearberry, [0005] Glycyrrhiza glabra and its derivatives, Chlorella vulgaris extract, perilla extract, and coconut fruit extract. Perilla extract is disclosed as a whitening agent in U.S. Pat. Nos. 5,980,904 and Japanese Publications 07025742, 07187989, 10265322, 2001163759, and 2001181173. Coconut fruit extract is disclosed as a whitening agent in Japanese Patent No. 2896815 B2. An extract of spongy mass of coconut tissue is employed in a tanning sunscreen composition in U.S. Pat. No. 5,756,099.
  • Skin and hair pigmentation is determined by the level of melanin present in the epidermis and hair fiber, respectively. Three different types of melanin are present in, for example, the epidermis: DHI-melanin, DHICA-melanin and pheomelanin. The different types of melanin vary in color or shade. DHI-melanin is the darkest and is blackish in color. DHICA-melanin is brownish in color. Pheomelanin is the lightest and is reddish in color. [0006]
  • Melanin is synthesized in specialized organelles called melanosomes within pigment-producing cells (melanocytes). Melanocytes respond to stimuli to regulate melanin synthesis. [0007]
  • Most conventional topical lightening agents act by interfering with the action of tyrosinase, the enzyme that catalyzes the conversion of the amino acid tyrosine to DOPAquinone. Previously, it has not been known that hypopigmenting could be achieved by inhibiting enzymes “downstream” from tyrosinase in the melanin synthesis pathway. It has now been discovered that the use of a melanin synthesis regulating agent that inhibits DOPAchrome tautomerase and/or DHICA-polymerase results in a composition with superior lightening, especially skin lightening. [0008]
  • It would be desirable to have a topical composition that provides enhanced levels of lightening, bleaching, hypopigmenting, whitening and/or depigmenting (hereinafter referred to individually and collectively as “lightening” or “lighten”). It would be further desirable to have a topical composition that contains lightening agents that acted to interfere with the conversion of DOPAchrome to DHI-melanin and DHICA-melanin. It would be yet further desirable to have a topical composition that contains lightening agents that act to inhibit or prevent the transfer (uptake) of melanin from the melanocytes to the keratinocytes. It would still yet be further desirable to have methods for lightening the skin, hair, nails and/or lips employing the compositions of the present invention. [0009]
  • SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide a composition for lightening of the skin. [0010]
  • It is an object of the present invention to provide a composition to alter/modify melanin synthesis in the skin. [0011]
  • It is an object of the present invention to provide a composition to inhibit or prevent the uptake of melanin by keratinocytes. [0012]
  • It is an object of the present invention to provide methods for effecting the foregoing. [0013]
  • These and other objects and advantages of the present invention are provided by a topical lightening composition comprising a melanin synthesis-regulating agent, and a vehicle. There is also a topical lightening composition comprising an extract of perilla leaf and a vehicle. There is also a topical lightening composition comprising a lightening agent selected from the group consisting of coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and combinations of any of the foregoing, and a vehicle. There are also methods for lightening the skin, hair, lips, and/or nails comprising topically applying any one of these compositions.[0014]
  • BRIEF DESCRIPTION OF THE DRAWING
  • FIG. 1 illustrates the results of the melanin uptake assay in the Examples.[0015]
  • DETAILED DESCRIPTION OF THE INVENTION
  • It was found surprising and unexpected that there were topical lightening compositions that provided enhanced levels of performance heretofore not possible. It was found possible to enhance lightening by inhibiting enzymes other than tyrosinase, specifically DOPAchrome tautomerase (DCT) and/or 5,6-dihydroxyindole-2-carboxylic acid polymerase (DHICA-polymerase). It was also found possible to enhance lightening by inhibiting and/or preventing the uptake of melanin by keratinocytes in, for example, the epidermis. [0016]
  • In its broadest aspects, the invention is not limited by any particular characterization of the physiological and/or chemical effects of topical lightening agents. However, the topical lightening agents useful in the compositions and methods of the present invention lighten the skin by regulating melanin production and inhibiting the uptake of melanin in the skin, hair, lips, and/or nails. [0017]
  • One embodiment of the present invention is the employment of a melanin synthesis-regulating agent individually, or in combination with a melanin uptake-inhibiting agent. When the melanin synthesis-regulating agent is present in an amount effective to inhibit DCT and/or DHICA polymerase, a superior lightening composition can be attained. It was heretofore unknown in the art that interference in this part of the melanin synthesis pathway could bring about lightening of the skin, hair, lips, and/or nails. A flow chart of the melanin synthesis pathway is as follows: [0018]
    Figure US20030129259A1-20030710-C00001
  • Moreover, the use of an additional agent that functions to inhibit the transfer (uptake) of melanin from the melanocytes to the keratinocytes further enhances the lightening efficacy of the present invention. [0019]
  • Examples of melanin synthesis-regulating agents include coconut water, coconut milk, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of each of the foregoing, or combinations of any of the foregoing. Coconut water that has been concentrated, especially by freeze-drying, is most preferred. [0020]
  • Examples of melanin uptake-inhibiting agents include extracts or oils derived from all or parts of the perilla plant, e.g. the leaf, seed, stem, and root. A preferred agent is extract of the perilla leaf. [0021]
  • Another embodiment of the present invention is the use of perilla leaf extract as a lightening agent in a topical lightening composition, either individually or in combination with another lightening agent. Perilla leaf extract provides an unexpected enhancement of topical lightening efficacy compared to extracts, concentrates, or oils of other parts of the perilla plant, i.e. the seed, stem and root. In addition to enhanced efficacy, the perilla leaf extract can provide topical lightening efficacy at a lower amount compared to extracts of other parts of the perilla plant. [0022]
  • Another embodiment of the present invention is the use of any of the following as a topical lightening agent in a composition: coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, or combinations of any of the foregoing. They can be used as the principal topical lightening agent or in combination with other lightening agents. Coconut water is preferred. A freeze-dried concentrate of coconut water is most preferred. Coconut water or the concentrate thereof is believed to provide superior lightening efficacy compared to extracts, concentrates, or oils of other parts of the coconut and/or coconut tree, i.e. the fruit, milk, shell, seed, leaf, and bark. [0023]
  • Topical lightening agents are present in the present composition at a level sufficient to induce the desired effect of lightening. The amount will vary depending upon the type of agent and the nature and level of desired effect. The lightening agent will typically be present from about 0.001 wt % to about 20 wt %, more preferably from about 0.01 wt % to about 5 wt %, and most preferably from about 0.1 wt % to about 2.5 wt %, based on the total weight of the composition. [0024]
  • The compositions of the present invention preferably include at least one, more preferably at least two, most preferably at least three, of the following ingredients: aloe barbadensis or an extract thereof, hydrolyzed soy protein, n-glucosamine, gamma-aminobutyric acid, a competitive inhibitor of melanocyte stimulating hormone (MSH) (e.g. hexapeptide-2), clintonia borealis (bluebeard lily) or an extract thereof, milk proteins, hydrolyzed milk proteins, sanguisorba officinalis (burnet), a glutathione reductase inhbitor (e.g. wheat germ) or extracts thereof. [0025]
  • The compositions of the present invention can be used to effectively lighten skin, hair, lips and nails be topically applying the composition having an effective amount of the topical lightening agent. To lighten the color or shade of hair, the present compositions should preferably be rubbed onto/into the scalp so that the composition can penetrate into the hair follicles or root shafts and be absorbed into the hair during the melanin production process. [0026]
  • The topical compositions of the present invention can be applied to treat a variety of skin conditions, including freckles, age spots, dark spots, hyperpigmentation, post-. inflammatory hyperpigmentation, (e.g. post-acne hyperpigmentation), discoloration, melasma, yellowing, and dark circles under the eyes. [0027]
  • The present compositions may include any vehicle known in the art. Suitable vehicles include, but are not limited to, water; one or more vegetable oils; esters such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dicapryl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, stearyl alcohol and behenyl alcohol; isoparaffins such as isooctane, isododecane and isohexadecane; silicone oils such as dimethicones and polysiloxanes; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyisobutene; polyols such as propylene glycol, glycerin, butylene glycol, pentylene glycol and hexylene glycol; or combinations thereof. [0028]
  • Further optionally, the present compositions may include additional skin whitening agents known in the art. Examples of useful agents include the following: hydroquinone, kojic acid, licorice and/or its derivatives, ascorbic acid/ascorbic acid derivatives, arbutin, bearberry, [0029] Glycyrrhiza glabra and its derivatives, and Chlorella vulgaris extract. Other whitening agents are disclosed in U.S. Pat. No. 5,980,904, which is incorporated by reference herein.
  • Further optionally, the present compositions may include one or more of the following ingredients: anesthetics, anti-allergenics, antifungals, antimicrobials, anti-inflammatories, antiseptics, chelating agents, colorants, emollients, exfollients, film formers, fragrances, humectants, insect repellents, lubricants, moisturizers, pharmaceutical agents, preservatives, skin protectants, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, or vitamins. [0030]
  • The compositions can be made into any suitable product form. Such product forms include, but are not limited to, a cream, lotion, ointment, gel, foam, pomade, aerosol spray, pump spray, a stick, towelette, or patch. [0031]
  • EXAMPLES
  • The effect of coconut water (freeze-dried concentrate) on the melanin synthesis pathway was demonstrated with various assays using mouse melanoma cells from the S91 cell line (hereinafter “cells”). The cells were cultured in 1:1 mixture of Ham F10+10% horse serum and DMEM+10% fetal bovine serum. All cell experiments were conducted in a humidified, 5% CO2 incubator at 37 degrees C. Cells were treated with 0.02% and 0.05% w/v concentrations of coconut water (freeze-dried concentrate) respectively for 24 hours. Cell extracts were attained at 24 hours, and the following assays were performed: DOPAchrome Tautomerase (Example 1) and DHICA Polymerase (Example 2). [0032]
  • Example 1 DOPAchrome Tautomerase Assay (Coconut Water)
  • DOPAchrome Tautomerase (DCT) activity was assayed according to the method disclosed in Chakraborty et al., 1998, Effect of arbutin on melanogenic proteins in human melanocytes, Pigment Cell Res. 11: 206-212. Specifically, ice-cold DOPA (0.5 mg per ml of 0.1 M sodium phosphate buffer, pH 6.8) was mixed with Ag[0033] 2O (30 mg Ag2O: 1 mg DOPA) for about 1 minute and filtered through a 0.22 μm Millipore filter. DCT was assayed spectrophotometrically by adding up to 0.1 ml cell extract to 0.5 ml of a solution of freshly prepared DOPAchrome (˜0.5 mg/ml). Reactions were carried out at room temperature in plastic cuvettes, and the disappearance of absorption at 475 nm was followed. Phenylthiourea (1 mM) was added to the reaction mixture, because the presence of tyrosinase in the cell extract can interfere with the assay. The percentage conversion of DOPAchrome was calculated per mg of protein extract and normalized against the control. It was demonstrated that 0.02% wt./vol. coconut water (freeze-dried) provided an average decrease in DOPAchrome conversion of 50% (42/58) as compared to the control.
  • Example 2 DHICA Polymerase Assay (Coconut Water)
  • A DHICA polymerase assay was done according to the method disclosed in Chakraborty et al., 1996, Polymerization of 5,6-dihydroxyindole-2-Carboxylic acid to melanin by the pmel17/silver locus protein, Eur. J. Biochem. 236: 180-188. Specifically, the cell extract (0.5 ml, 150-200 μg protein) was passed through a wheat germ agglutinin column (1 ml bed volume) equilibrated with lysis buffer. The bound material was eluted with 0.5 ml 1M N-acetyl glucosamine, which contains crude DHICA polymerization factor and other melanogenic proteins. A reaction mixture of 0.5 ml containing either the enzyme preparation to be measured (20 μg protein from wheat germ agglutinin eluates) or the appropriate buffer blank, DHICA (0.5 mM), and 100 mM sodium phosphate buffer, pH 7.0. Phenylthiourea was also included to inhibit endogenous tyrosinase activity in the preparation. [0034]
  • Spectrophotomeric reading of the absorbance of the reaction mixture was taken at T=0 and T=4 hours time points at 400 nm. DHICA-melanin, but not DHICA itself, has been shown to absorb light at these wavelengths (Orlow et al., 1992, Synthesis and characterization of melanins from dihydroxyindole-2-carboxylic acid and dihydroxyndole, Pigment Cell Res. 5: 113-121). An increase in absorbance over that seen in blank tubes was defined as specific DHICA polymerization factor activity. It was demonstrated that 0.02% wt./vol. coconut water (freeze-dried) provided an average of 52.5% (55%/50%) decrease in DOPAchrome conversion as compared to the control. At 0.05% wt./vol. coconut water (freeze-dried) provided an average decrease of 75% (74/76) in DOPAchrome conversion as compared to the control. [0035]
  • Example 3 Melanosome Uptake Assay (Perilla Leaf Extract)
  • Melanosome Isolation [0036]
  • Confluent cultures of B16 melanocytes produce moderate levels of melanosomes. However, to induce elevated melanosome production in this cell line, semi-confluent (60%) cultures of B16 cells were treated for approximately 36 hours with normal growth medium supplemented with 10 mM ammonium chloride (final conc.). The medium was then aspirated and the hypermelanotic cells were washed (2×2 ml) with distilled water to provide a hypotonic stress to the cells. An aliquot (2 ml) of a hypotonic lysis solution (0.02% NP-40 in water) was added to each plate and the plates were incubated for approximately 5 min at room temperature. Following verification of cell lysis using light microscopy, the cellular material from three (3) culture plates were pooled in a 15 ml conical tube and centrifuged at approximately (200×g) for 5 minutes to remove cellular debris. The resulting supernatant containing melanosomes was transferred to a clean 15 ml conical tube and centrifuged (850×g) for 20 minutes. The resulting pellet containing the isolated melanosomes were resuspended in 1 ml of Phosphate Buffered Saline (PBS) and stored at 4° C. until used. [0037]
  • Treatment of Keratinocytes with Melanosomes [0038]
  • The normal human epidermal keratinocytes (NHEKs) (available from Clonetics, Inc.) were plated in the wells of 24-well plates at a density of 200,000 cells/well. Approximately 24 hours later, the growth medium was replaced with 1 ml of the appropriate growth medium (i.e., DMEM/KGM-2) containing the melanosome preparation with or without additional treatment conditions. The cells were treated with different concentations of perilla leaf extract (powder form or aqueous form). The cells were then returned to the incubator for approximately 1.5 hours. For these studies, each well of keratinocytes was treated with the amount of melanosomes isolated from a single plate of B16 cells. [0039]
  • In some experiments, the 24 well plates of treated keratinocytes were centrifuged for 15 minutes at 1,000 rpm to facilitate the deposition of the melanosomes onto the surface membranes of the keratinocytes. The plates were then returned to the incubator for 1.25 hours. [0040]
  • Analysis of Melanosome Uptake [0041]
  • For analysis, the cells in each well of keratinocytes were rinsed (3×1 ml) with PBS, removed from the plate using trypsin/EDTA, washed with PBS. To analyze the uptake of melanosomes by the keratinocytes, the internalized melanin was extracted from the cells according to a modified method of Bessou-Touya, S., et al. (Chimeric human epidermal reconstructs to study the role of melanocytes and keratinocytes in pigmentation and photoprotection. J. Invest. Dermatol., 111:1103-1108, 1998) and quantified spectrophotometrically by determining the melanin-specific absorbance at 405 nm. [0042]
  • Results [0043]
  • Melanocytes synthesize melanin and deposits onto melanosomes. Visual manifestation of skin color is due to presence of melanin/melanosomes in keratinocytes. Melanosomes are taken up by keratinocytes and the rate of uptake, retention and processing of melanosomes in the keratinocytes is a key determinant of skin color. Thus, the internalized melanin value reflects the amount of melanin/melanosome uptake and retention by the keratinocytes. Thus, lower internalized melanin values, particularly internalized melanin values that are less than the control with melanin, indicate that melanin uptake by the keratinocytes has been inhibited. As illustrated in FIG. 1, internalized melanin values for perilla leaf extract were lower than internalized melanin values of the control with melanin. [0044]
  • It should be understood that the foregoing description is only illustrative of the present invention. Various alternatives and modifications can be devised by those skilled in the art without departing from the invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications and variances which fall within the scope of the appended claims. [0045]

Claims (30)

What is claimed is
1. A composition, comprising:
a) a topical lightening agent in an amount effective to inhibit DOPAchrome tautomerase, DHICA polymerase, or both; and
b) a vehicle.
2. The composition of claim 1, wherein the topical lightening agent has a melanin synthesis-regulating agent.
3. The composition of claim 2, wherein the melanin synthesis-regulating agent is selected from the group consisting of coconut water, palm water, concentrates of the foregoing, and any combinations thereof.
4. The composition of claim 2, wherein the melanin synthesis-regulating agent is a concentrate of coconut water.
5. The composition of claim 2, wherein the melanin synthesis-regulating agent is selected from the group consisting of coconut milk, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and any combinations thereof.
6. The composition of claim 2, wherein the topical lightening agent further has a melanin uptake-inhibiting agent in an amount effective to inhibit the transfer of melanin from melanocytes to keratinocytes.
7. The composition of claim 6, wherein the melanin uptake-inhibiting agent is an extract of perilla.
8. The composition of claim 6, wherein the melanin uptake-inhibiting agent is an extract selected from the group consisting of perilla leaf, perilla seed, perilla stem, and perilla root.
9. The composition of claim 6, wherein the melanin synthesis-regulating agent is a concentrate of coconut water and the melanin uptake-inhibiting agent is a perilla leaf extract.
10. The composition of claim 1, wherein the topical lightening agent is present in an amount about 0.001 to about 20 wt % based on the total weight of the composition.
11. The composition of claim 1, wherein the topical lightening agent is present in an amount about 0.01 to about 5 wt % based on the total weight of the composition.
12. The composition of claim 1, wherein the topical lightening agent is present in an amount about 0.1 to about 2.5 wt % based on the total weight of the composition.
13. The composition of claim 1, wherein the composition is in a product form selected from the group consisting of a cream, a lotion, an ointment, a gel, a foam, a pomade, an aerosol spray, a pump spray, a stick, a towelette, and a patch.
14. A method of lightening skin, hair, lips, and/or nails, comprising: applying topically to the skin, scalp, hair, lips, and/or nails the composition according to claim 1.
15. The method of claim 14, wherein the composition is topically applied to treat a skin condition selected from the group consisting of freckles, age spots, dark spots, hyperpigmentation, post-inflammatory hyperpigmentation, discoloration, melasma, yellowing, dark circles under the eyes, and any combinations thereof.
16. A topical composition, comprising:
a) an extract of perilla leaf and
b) a vehicle.
17. The composition of claim 16, wherein the perilla leaf extract is present in an amount effective to inhibit the uptake of melanin by keratinocytes in the skin.
18. The composition of claim 16, wherein the perilla leaf extract is present in an amount about 0.001 to about 20 wt % based on the total weight of the composition.
19. The composition of claim 16, wherein the perilla leaf extract is present in an amount about 0.01 to about 5 wt % based on the total weight of the composition.
20. The composition of claim 16, wherein the perilla leaf extract is present in an amount about 0.1 to about 2.5 wt % based on the total weight of the composition.
21. The composition according to claim 16, wherein the composition is in a product form selected from the group consisting of a cream, a lotion, an ointment, a gel, a foam, a pomade, an aerosol spray, a pump spray, a stick, a towelette, and a patch.
22. A method of lightening skin, hair, lips, and/or nails, comprising: applying topically to the skin, scalp, hair and/or nails the composition according to claim 17.
23. The method of claim 22, wherein the composition is topically applied to treat a skin condition selected from the group consisting of freckles, age spots, dark spots, hyperpigmentation, post-inflammatory pigmentation, discoloration, yellowing, melasma, dark circles under the eyes, and any combinations thereof.
24. A composition, comprising:
a) a topical lightening agent selected from the group consisting of coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and any combinations thereof; and
c) a vehicle,
wherein the topical lightening agent is present in an amount effective to inhibit DOPAchrome tautomerase, DHICA polymerase or both.
25. The composition of claim 24, wherein the topical lightening agent is coconut water or a concentrate thereof.
26. The composition of claim 26, wherein the topical lightening agent is present in an amount about 0.001 to about 20 wt % based on the total weight of the composition.
27. The composition of claim 26, wherein the topical lightening agent is present in an amount about 0.01 to about 5 wt % based on the total weight of the composition.
28. The composition of claim 26, wherein the topical lightening agent is present in an amount about 0.1 to about 2.5 wt % based on the total weight of the composition.
29. A method of lightening skin, hair, lips, and/or nails comprising: applying topically to the skin, scalp, lips, hair, and/or nails the composition according to claim 24.
30. The method of claim 29, wherein the composition is topically applied to treat a skin condition selected from the group consisting of freckles, age spots, dark spots, hyperpigmentation, post-inflammatory pigmentation, discoloration, yellowing, melasma, dark circles under the eyes, and any combinations thereof.
US10/034,186 2001-12-28 2001-12-28 Topical lightening compostitions and methods of use Abandoned US20030129259A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/034,186 US20030129259A1 (en) 2001-12-28 2001-12-28 Topical lightening compostitions and methods of use

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US10/034,186 US20030129259A1 (en) 2001-12-28 2001-12-28 Topical lightening compostitions and methods of use
CA 2411222 CA2411222C (en) 2001-12-28 2002-11-06 Topical lightening compositions and methods of use
JP2002348249A JP4601898B2 (en) 2001-12-28 2002-11-29 Topical lightening compositions and methods of use thereof
MXPA02011912 MXPA02011912A (en) 2001-12-28 2002-12-02 Lightening compositions and methods of use.
US10/319,781 US7014844B2 (en) 2001-12-28 2002-12-13 Lightening compositions and methods of use
EP20020028448 EP1325738B1 (en) 2001-12-28 2002-12-19 Non therapeutical methods and medical uses for depigmenting the skin
DE2002618125 DE60218125T2 (en) 2001-12-28 2002-12-19 A non-therapeutic method and therapeutic applications for skin depigmentation
PL357931A PL211313B1 (en) 2001-12-28 2002-12-20 Brightening compositions for local application and method of using them
CN 02159806 CN1293862C (en) 2001-12-28 2002-12-27 Local color-lightening compound and its application method
US11/215,874 US7544351B2 (en) 2001-12-28 2005-08-31 Topical lightening compositions and methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/319,781 Continuation-In-Part US7014844B2 (en) 2001-12-28 2002-12-13 Lightening compositions and methods of use
US11/215,874 Continuation US7544351B2 (en) 2001-12-28 2005-08-31 Topical lightening compositions and methods of use

Publications (1)

Publication Number Publication Date
US20030129259A1 true US20030129259A1 (en) 2003-07-10

Family

ID=21874835

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/034,186 Abandoned US20030129259A1 (en) 2001-12-28 2001-12-28 Topical lightening compostitions and methods of use
US10/319,781 Expired - Fee Related US7014844B2 (en) 2001-12-28 2002-12-13 Lightening compositions and methods of use
US11/215,874 Active US7544351B2 (en) 2001-12-28 2005-08-31 Topical lightening compositions and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/319,781 Expired - Fee Related US7014844B2 (en) 2001-12-28 2002-12-13 Lightening compositions and methods of use
US11/215,874 Active US7544351B2 (en) 2001-12-28 2005-08-31 Topical lightening compositions and methods of use

Country Status (8)

Country Link
US (3) US20030129259A1 (en)
EP (1) EP1325738B1 (en)
JP (1) JP4601898B2 (en)
CN (1) CN1293862C (en)
CA (1) CA2411222C (en)
DE (1) DE60218125T2 (en)
MX (1) MXPA02011912A (en)
PL (1) PL211313B1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060198809A1 (en) * 2005-03-04 2006-09-07 Woodridge Labs, Inc. Gamma-amino butyric acid composition
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
US20120156144A1 (en) * 2002-10-25 2012-06-21 Foamix Foamable Compositions, Kits and Methods for Hyperhidrosis
US9023327B2 (en) * 2012-08-30 2015-05-05 Avon Products, Inc. DICKKOPF-1 expression modulating compositions and uses thereof
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US20030129259A1 (en) * 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20040126351A1 (en) * 2002-12-26 2004-07-01 Avon Products, Inc. Topical composition having natural skin anti-irritant ingredient and method of use
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
WO2005055962A1 (en) 2003-12-15 2005-06-23 Kuraray Co., Ltd. External preparations for skin
JP5311760B2 (en) * 2007-05-25 2013-10-09 雪印メグミルク株式会社 Whitening agents
WO2009090558A2 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
FR2926720B1 (en) * 2008-01-24 2011-09-09 Jean Noel Thorel Cosmetic composition for blocking the pigmentation of the skin induced by UV radiation
ES2327201B1 (en) * 2008-04-23 2010-07-23 Ignacio Umbert Millet Personalized pharmaceutical composition for skin rejuvenation containing retinoic acid.
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
US20100158842A1 (en) * 2008-10-09 2010-06-24 Spectrum Dynamics Llc Natural skin whitener: 4-hydroxy-oxindole-3-acetic acid
FR2943542B1 (en) * 2009-03-31 2012-05-25 Lvmh Rech Methode care cosmetic anti-aging by stimulating the activity of mitochondrial aconisate.
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
FR2957801A1 (en) * 2009-07-31 2011-09-30 Georges Camprasse Extracting active ingredients in mature Coco nucifera water, where the water is taken in a sterile manner by suction using a trocar connected to a peristaltic pump, introduced in one of germinal centers of the nut previously decontaminated
ES2687780T3 (en) * 2009-09-30 2018-10-29 Shiseido Company, Ltd. Heparanase inhibitor activity
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
JP2011214909A (en) * 2010-03-31 2011-10-27 Daiichi Sankyo Healthcare Co Ltd Method for detecting incorporation and transportation of melanosome by keratinocyte
EP2613762B1 (en) 2010-09-10 2018-10-17 Mary Kay, Inc. Topical skin care formulations comprising jaboticaba fruit pulp
WO2013192073A2 (en) 2012-06-18 2013-12-27 The Procter & Gamble Company Method of improving the appearance of aging skin
EP2890359B1 (en) * 2012-08-30 2016-10-05 Avon Products, Inc. Dickkopf-1 expression modulating compositions and uses thereof
JP6375087B2 (en) * 2013-03-04 2018-08-15 共栄化学工業株式会社 Cosmetics
EP3010481A4 (en) * 2013-06-19 2017-01-18 ELC Management LLC Methods, compositions, and kit for whitening hyper pigmented spots on skin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993835A (en) * 1997-04-30 1999-11-30 Mishima; Yutaka Skin-whitening agent
US6551606B1 (en) * 1999-06-10 2003-04-22 Coty B.V. Cosmetic product containing enzymes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2041400A5 (en) * 1969-04-23 1971-01-29 Baudot Georges Production of vegetable milks
US3671643A (en) * 1969-09-15 1972-06-20 Oreal Treatment of excessive sebaceous glands secretion with substituted cysteamine compounds
US4372296A (en) * 1980-11-26 1983-02-08 Fahim Mostafa S Treatment of acne and skin disorders and compositions therefor
JP2896815B2 (en) * 1991-01-29 1999-05-31 有限会社野々川商事 Cosmetics
KR930006432B1 (en) * 1991-04-10 1993-07-16 이순목 Pharmaceutical compositions for treating acne
JPH0725742A (en) 1993-07-15 1995-01-27 Kao Corp Fair-skinning cosmetic
JP2884466B2 (en) 1993-12-27 1999-04-19 長瀬産業株式会社 Perilla extract, their preparation and whitening cosmetics containing the same
JP2952636B2 (en) * 1993-12-27 1999-09-27 長瀬産業株式会社 Melanogenesis inhibitors, whitening cosmetics containing method and it's production
JPH08291057A (en) * 1995-02-22 1996-11-05 Yuutoku Yakuhin Kogyo Kk Cataplasm
CA2224691A1 (en) * 1995-06-23 1997-01-09 Vincent J. Hearing, Jr. Depigmenting activity of agouti signal protein and peptides thereof
AU734341B2 (en) * 1996-08-02 2001-06-14 Shiseido Company Ltd. Composition for enhancing hyaluronic acid productivity and method for preparing same
JPH10265322A (en) 1997-03-19 1998-10-06 Shiseido Co Ltd Skin preparation for external use
AU3368999A (en) * 1998-03-31 1999-10-18 Mary Kay Inc. Skin lightening composition containing magnesium ascorbyl phosphate and uninontan-u34tm (extract formulation of cucumber extract and lemon extract)
US5980904A (en) 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
JP4015792B2 (en) 1999-12-10 2007-11-28 豊也 加藤 Whitening agents and skin external preparation containing the same as an active ingredient
JP2001181173A (en) 1999-12-27 2001-07-03 Kose Corp Bleaching preparation for external use
CN1323577A (en) * 2000-05-17 2001-11-28 刘晨 Facial cleaning milk made of coconut milk
JP2002284663A (en) 2001-03-27 2002-10-03 Ichimaru Pharcos Co Ltd Cosmetic composition
US20030129259A1 (en) * 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
JP3803757B2 (en) 2003-09-24 2006-08-02 アトーテック株式会社 Ultrafine particles producing device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993835A (en) * 1997-04-30 1999-11-30 Mishima; Yutaka Skin-whitening agent
US6551606B1 (en) * 1999-06-10 2003-04-22 Coty B.V. Cosmetic product containing enzymes

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20120156144A1 (en) * 2002-10-25 2012-06-21 Foamix Foamable Compositions, Kits and Methods for Hyperhidrosis
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20060198809A1 (en) * 2005-03-04 2006-09-07 Woodridge Labs, Inc. Gamma-amino butyric acid composition
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9023327B2 (en) * 2012-08-30 2015-05-05 Avon Products, Inc. DICKKOPF-1 expression modulating compositions and uses thereof

Also Published As

Publication number Publication date
EP1325738A3 (en) 2004-05-06
CA2411222C (en) 2010-01-19
DE60218125D1 (en) 2007-03-29
CN1494886A (en) 2004-05-12
EP1325738B1 (en) 2007-02-14
US20050287089A1 (en) 2005-12-29
EP1325738A2 (en) 2003-07-09
CA2411222A1 (en) 2003-06-28
JP2003212714A (en) 2003-07-30
PL357931A1 (en) 2003-06-30
PL211313B1 (en) 2012-05-31
JP4601898B2 (en) 2010-12-22
DE60218125T2 (en) 2007-11-22
US20030157202A1 (en) 2003-08-21
US7544351B2 (en) 2009-06-09
US7014844B2 (en) 2006-03-21
MXPA02011912A (en) 2005-07-29
CN1293862C (en) 2007-01-10

Similar Documents

Publication Publication Date Title
US5698184A (en) Compositions and methods for skin tanning and protection
KR100345096B1 (en) Cosmetic and/or dermatological composition containing at least one extract of mulberry, at least one extract of skullcap and at least one salicylic acid derivative
AU2003303628B2 (en) Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
KR100928211B1 (en) Composition that reduces the composition and the acne lesions for the treatment of damage caused by the sun's rays
CA2749750C (en) Skin care compositions and methods of use thereof
CA2657703C (en) Use of a rice protein hydrolysate as pigmenting active principle
FR2880802A1 (en) Cosmetic or dermopharmaceutical composition containing an extract of Euglena
KR20060122844A (en) Compositions containing mixtures of tetrapeptides and tripeptides
JP2002193738A (en) Use of at least one extract from at least one azalea plant in composition for treating symptom of skin aging
EP1581177B1 (en) Cutaneous metabolic bio-activator
US9445988B2 (en) Extracts of Tetraselmis sp
EP1549331B2 (en) Use of purslane to treat facial wrinkles
US7429391B2 (en) Holistic composition and method for reducing skin pigmentation
US20070274937A1 (en) Use of a Cruciferous Protein Hydrolysate as a Depigmentation Agent or For a Cosmetic and/or Pharmaceutical Composition
KR101578342B1 (en) Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method
KR20030061834A (en) Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa
KR101537834B1 (en) Cosmetic compositions comprising exopolysaccharides derived from microbial mats
EP1278532B1 (en) Plant extract of the olea europaea species as no-synthase inhibitor and uses
US7014844B2 (en) Lightening compositions and methods of use
ES2689170T3 (en) cosmetic uses of modified yeast extracts stressed and related compositions
WO1998005299A1 (en) Novel cosmetic compositions for beautifying and lightening skin
KR100866302B1 (en) Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant argania spinosa
US20100080761A1 (en) Extracts of Isochrysis sp.
US8709511B2 (en) External preparation composition for skin comprising ginseng flower or ginseng seed extracts
KR101089071B1 (en) Use of ellagic acid for the treatment of canities

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVON PRODUCTS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAHALINGAM, HARISH;JONES, BRIAN;MENON, GOPINATHAN K.;AND OTHERS;REEL/FRAME:012727/0675;SIGNING DATES FROM 20020305 TO 20020307

AS Assignment

Owner name: AVON PRODUCTS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAHALINGAM, HARISH;JONES, BRIAN;MENON, GOPINATHAN K.;AND OTHERS;REEL/FRAME:013942/0073;SIGNING DATES FROM 20030307 TO 20030317

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION